Literature DB >> 24309124

Pretreatment advanced imaging in patients with stroke treated with IV thrombolysis: evaluation of a multihospital data base.

J S McDonald1, J Fan, D F Kallmes, H J Cloft.   

Abstract

BACKGROUND AND
PURPOSE: CT angiography, CT perfusion, and MR imaging have all been advocated as potentially useful in treatment planning for patients with acute ischemic stroke. We evaluated a large multihospital data base to determine how the use of advanced imaging is evolving in patients treated with intravenous thrombolysis.
MATERIALS AND METHODS: Patients with acute ischemic stroke receiving IV thrombolytic therapy from 2008 to 2011 were identified by using the Premier Perspective data base. Mortality and discharge to long-term care rates were compared following multivariate logistic regression between patients who received head CT only versus those who received CTA without CT perfusion, CT perfusion, or MR imaging.
RESULTS: Of 12,429 included patients, 7305 (59%) were in the CT group, 2359 (19%) were in the CTA group, 848 (7%) were in the CTP group, and 1917 (15%) were in the MR group. From 2008 to 2011, the percentage of patients receiving head CT only decreased from 64% to 55%, while the percentage who received cerebral CT perfusion increased from 3% to 8%. The use of CT angiography and MR imaging marginally increased (1%-2%). Outcomes were similar between CT only and advanced imaging patients, except discharge to long-term care was slightly more frequent in the CTP group (OR = 1.17 [95% CI, 0.96-1.43]; P = .0412) and MR group (OR = 1.14 [95% CI, 1.01-1.28]; P = .0177) and mortality was lower in the MR group (OR = 0.64 [95% CI, 0.52-0.79]; P < .0001).
CONCLUSIONS: Use of advanced imaging is increasing in patients treated with IV thrombolysis. While there were differences in outcomes among imaging groups, the clinical effect of advanced imaging remains unclear.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24309124     DOI: 10.3174/ajnr.A3797

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  5 in total

1.  Updated Trends, Disparities, and Clinical Impact of Neuroimaging Utilization in Ischemic Stroke in the Medicare Population: 2012 to 2019.

Authors:  Jason J Wang; Casey E Pelzl; Artem Boltyenkov; Jeffrey M Katz; Jennifer Hemingway; Eric W Christensen; Elizabeth Rula; Pina C Sanelli
Journal:  J Am Coll Radiol       Date:  2022-04-25       Impact factor: 6.240

2.  Is CT perfusion helpful in the treatment allocation of patients with acute ischemic stroke? An expert-opinion analysis.

Authors:  Laura Strada; Jonathan Y Streifler; Bruno Del Sette; Matteo Puntoni; Antonio Castaldi; Daria Bianchini; Massimo Del Sette
Journal:  Neurol Sci       Date:  2017-07-19       Impact factor: 3.307

3.  Arterial Obstruction on Computed Tomographic or Magnetic Resonance Angiography and Response to Intravenous Thrombolytics in Ischemic Stroke.

Authors:  Grant Mair; Rüdiger von Kummer; Alessandro Adami; Philip M White; Matthew E Adams; Bernard Yan; Andrew M Demchuk; Andrew J Farrall; Robin J Sellar; Eleni Sakka; Jeb Palmer; David Perry; Richard I Lindley; Peter A G Sandercock; Joanna M Wardlaw
Journal:  Stroke       Date:  2016-12-22       Impact factor: 7.914

Review 4.  Imaging of acute stroke prior to treatment: current practice and evolving techniques.

Authors:  G Mair; J M Wardlaw
Journal:  Br J Radiol       Date:  2014-06-17       Impact factor: 3.039

5.  Observer reliability of CT angiography in the assessment of acute ischaemic stroke: data from the Third International Stroke Trial.

Authors:  Grant Mair; Rüdiger von Kummer; Alessandro Adami; Philip M White; Matthew E Adams; Bernard Yan; Andrew M Demchuk; Andrew J Farrall; Robin J Sellar; Rajesh Ramaswamy; Daisy Mollison; Elena V Boyd; Mark A Rodrigues; Karim Samji; Andrew J Baird; Geoff Cohen; Eleni Sakka; Jeb Palmer; David Perry; Richard Lindley; Peter A G Sandercock; Joanna M Wardlaw
Journal:  Neuroradiology       Date:  2014-10-07       Impact factor: 2.804

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.